Guillaume Onyeaghala

Dr. Guillaume Onyeaghala

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
EPElizabeth J. Polter
Elizabeth J. Polter
GOGuillaume Onyeaghala
Guillaume Onyeaghala
PLPamela Lutsey
Pamela Lutsey
AFAaron R. Folsom
Aaron R. Folsom
CJCorinne E. Joshu
Corinne E. Joshu
APAnna Prizment
Anna Prizment
Background: Laboratory and epidemiologic research suggests a protective role of magnesium in colorectal cancer development. We estimated the associations of serum and dietary magnesium with colorectal cancer incidence in the Atherosclerosis Risk in Communities (ARIC) study. Methods: Serum magnesium concentration was measured in blood collected twice (1987–1989 and 1990–1992) and averaged. Dietary magnesium was assessed by food-frequency questionnaire administered twice (1987–1989 and 1993–1995) and averaged. For both dietary and serum magnesium, the averaged measures were categorized into quintiles for analysis. Analyses included 315 colorectal cancer cases among 13,009 participants for serum magnesium (followed for a median of 20.4 years), and 256 cases among 10,971 participants for dietary magnesium (followed for a median of 17.5 years). Cox proportional hazards regression was used to calculate multivariable-adjusted HRs and 95% confidence intervals (CI). Results: Multivariable-adjusted HRs (95% CI) of colorectal cancer for the highest four quintiles compared with the first quintile of serum magnesium were as follows: Q2: 0.70 (0.49–0.99); Q3: 0.68 (0.47–1.00); Q4: 0.87 (0.62–1.21); and Q5: 0.79 (0.57–1.11; Ptrend = 0.04). An inverse association was present in females (HR for Q5 vs. Q1: 0.59, 95% CI: 0.36–0.98, Ptrend = 0.01), but not males (HR for Q5 vs. Q1: 1.10, 95% CI: 0.67–1.79, Ptrend = 0.92; Pinteraction = 0.34). Dietary magnesium was not statistically significantly associated with colorectal cancer risk. Conclusions: Our study found a higher risk of colorectal cancer with lower serum magnesium among females, but not males. Impact: If our findings are confirmed, maintaining adequate serum magnesium levels may be important for colorectal cancer prevention.

24 December 2019 in Cancer
Verified
Journal Article
Closed access
PDF file
GOGuillaume Onyeaghala
Guillaume Onyeaghala
ALAnna K. Lintelmann
Anna K. Lintelmann
CJCorrine E. Joshu
Corrine E. Joshu
PLPamela L. Lutsey
Pamela L. Lutsey
AFAaron R. Folsom
Aaron R. Folsom
APAnna Prizment
Anna Prizment

3 August 2022 in Gut Microbes
Verified
Journal Article
Open access
MKMohammad Haneef Khan
Mohammad Haneef Khan
GOGuillaume Onyeaghala
Guillaume Onyeaghala
ARArmin Rashidi
Armin Rashidi
Shernan HoltanShernan Holtan
Shernan Holtan
AKAlexander Khoruts
Alexander Khoruts
Christopher StaleyChristopher Staley
Christopher Staley
The intestinal microbiota produces β-glucuronidase that plays an essential role in the metabolism of the immunosuppressant mycophenolate mofetil (MMF). This drug is commonly used in organ and hematopoietic cell transplantation (HCT), with variations in dosing across transplant types. We hypothesized that β-glucuronidase activity differs between transplant types, which may account for differences in dosing requirements. We evaluated fecal β-glucuronidase activity in patients receiving MMF post-allogeneic HCT and post-kidney transplant. Kidney transplant patients had significantly greater β-glucuronidase activity (8.48 ± 6.21 nmol/hr/g) than HCT patients (3.50 ± 3.29 nmol/hr/g; P = .001). Microbially mediated β-glucuronidase activity may be a critical determinant in the amount of mycophenolate entering the systemic circulation and an important factor to consider for precision dosing of MMF.

5 June 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GOGuillaume Onyeaghala
Guillaume Onyeaghala
JLJohn Lane
John Lane
NPNathan Pankratz
Nathan Pankratz
HNHeather H. Nelson
Heather H. Nelson
BTBharat Thyagarajan
Bharat Thyagarajan
APAnna Prizment
Anna Prizment
Pancreatic tumor cells may avoid immune surveillance by releasing the transmembrane major histocompatibility complex class I chain-related A (MICA) protein in soluble form (s-MICA). We hypothesized that the presence of the A5.1 polymorphism in the MICA gene, which encodes a truncated MICA protein, is associated with higher s-MICA levels and increased pancreatic cancer risk. MICA alleles and s-MICA levels were measured in 121 pancreatic cancer cases and 419 controls. General linear regression with a log transformation assessed geometric means of s-MICA levels across MICA alleles. Unconditional logistic regression was used to calculate the odds ratio (OR) and 95% confidence intervals (CI) for pancreatic cancer associated with MICA alleles. After multivariate adjustment, participants with at least one copy of the A5.1 allele versus no A5.1 allele had 1.35 (95% CI: 1.05–1.74) times greater s-MICA levels (1.65 times higher for cases and 1.28, for controls) and increased risk of pancreatic cancer (OR = 1.91, 95% CI: 1.05–3.48). Our study suggests higher risk of pancreatic cancer among those with the MICA A5.1 polymorphism, which may be explained by an increase in s-MICA secretion and impaired immune response. These findings provide further evidence at the genetic and molecular level of the important role of MICA in pancreatic cancer development, and may have important implications with regards to pancreatic cancer screening.

11 January 2023 in Clinical Transplantation
Verified
Journal Article
Closed access
KRKevin A. Reininger
Kevin A. Reininger
GOGuillaume Onyeaghala
Guillaume Onyeaghala
TATeresa Anderson‐Haag
Teresa Anderson‐Haag
DSDavid S. Schladt
David S. Schladt
BWBaolin Wu
Baolin Wu
PJPamala A. Jacobson
Pamala A. Jacobson

12 July 2024 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
ASAbdelrahman Saqr
Abdelrahman Saqr
MAMahmoud Al‐Kofahi
Mahmoud Al‐Kofahi
MMMoataz Mohamed
Moataz Mohamed
CDCasey Dorr
Casey Dorr
RRRory P. Remmel
Rory P. Remmel
PJPamala A. Jacobson
Pamala A. Jacobson
Aims: Tacrolimus, metabolized by CYP3A4 and CYP3A5 enzymes, is susceptible to drug–drug interactions (DDI). Steroids induce CYP3A genes to increase tacrolimus clearance, but the effect is variable. We hypothesized that the extent of the steroid–tacrolimus DDI differs by CYP3A4/5 genotypes.Methods: Kidney transplant recipients (n = 2462) were classified by the number of loss of function alleles (LOF) (CYP3A5*3, *6 and *7 and CYP3A4*22) and steroid use at each tacrolimus trough in the first 6 months post‐transplant. A population pharmacokinetic analysis was performed by nonlinear mixed‐effect modelling (NONMEM) and stepwise covariate modelling to define significant covariates affecting tacrolimus clearance. A stochastic simulation was performed and translated into a Shiny application with the mrgsolve and Shiny packages in R.Results: Steroids were associated with modestly higher (3%–11.8%) tacrolimus clearance. Patients with 0‐LOF alleles receiving steroids showed the greatest increase (11.8%) in clearance compared to no steroids, whereas those with 2‐LOFs had a negligible increase (2.6%) in the presence of steroids. Steroid use increased tacrolimus clearance by 5% and 10.3% in patients with 1‐LOF and 3/4‐LOFs, respectively.Conclusions: Steroids increase the clearance of tacrolimus but vary slightly by CYP3A genotype. This is important in individuals of African ancestry who are more likely to carry no LOF alleles, may more commonly receive steroid treatment, and will need higher tacrolimus doses.